Research References

Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1)

Garvey WT, Frias JP, Jastreboff AM, et al. · New England Journal of Medicine · 2025

Phase 3 trial with 3,417 adults showing CagriSema produced 20.4% average weight loss over 68 weeks, with 60% losing 20% or more and 23% losing 30% or more of body weight.

Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2)

Davies MJ, Aroda VR, Collins BS, et al. · New England Journal of Medicine · 2025

Phase 3 trial with 1,206 adults with type 2 diabetes showing CagriSema produced 13.7% weight loss and 73.5% of participants achieved HbA1c of 6.5% or less over 68 weeks.

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes

Kong BS, Lee C, Cho YM, et al. · Experimental & Molecular Medicine · 2025

Showed that MOTS-c treatment reduced signs of aging in pancreatic cells and improved their function, with clinical relevance supported by finding that MOTS-c levels are lower in type 2 diabetes patients compared to healthy controls.

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee J, Burgess J · Journal of Clinical Medicine · 2025

Pilot study in two healthy adults showing IV BPC-157 infusions up to 20 mg were well tolerated with no adverse events or clinically meaningful changes in vital signs, ECG, or laboratory biomarkers.

Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties

Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L · International Journal of Molecular Sciences · 2025

A systematic review confirming that Epithalamin required 1,000-fold higher doses than synthetic Epithalon to achieve comparable antioxidant effects. The review also noted that Epithalon was not detected in human pineal tissue until 2017.

Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

Al-dulaimi S, Thomas R, Matta S, Roberts T · Research Square (Preprint) · 2025

This study found that Epithalon increases telomere length in normal cells through hTERT upregulation with 12-fold increases in expression, while cancer cells showed telomere extension through the Alternative Lengthening of Telomeres mechanism instead.

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI

Bourgeois B, Gui T, Lazaro D, et al. · Nature Communications · 2025

Provided detailed structural and mechanistic insight into exactly how FOXO4-DRI interacts with the p53 protein, confirming that the disordered transactivation domain of p53 is the specific target of both endogenous FOXO4 and the therapeutic FOXO4-DRI peptide.

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Malhotra A, Grunstein RR, Engelman HM, et al. · New England Journal of Medicine · 2024

The SURMOUNT-OSA trial demonstrated that tirzepatide reduced sleep apnea severity by up to 62.8% as measured by apnea-hypopnea index at 52 weeks, along with improvements in blood pressure and metabolic markers.

A review of an investigational drug retatrutide

Kaur M, Misra S. · European Journal of Clinical Pharmacology · 2024

Comprehensive review of retatrutide's pharmacology, clinical trial data, and potential as a next-generation triple agonist for obesity and type 2 diabetes treatment.

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

Li W, et al. · Cell Discovery · 2024

Structural biology study revealing how retatrutide's molecular design allows it to simultaneously activate three different hormone receptors, explaining its superior efficacy compared to single and dual agonists.

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages

Berlanga-Acosta J, et al. · Frontiers in Pharmacology · 2024

Showed that GHRP-6 prevented myocardial fiber damage and ventricular dilation, preserved left ventricular systolic function, protected multiple organs from doxorubicin toxicity, and reduced morbidity and mortality through antioxidant defense and Bcl-2 upregulation.

Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes

Kraskovskaya N, et al. · International Journal of Molecular Sciences · 2024

Showed that short peptides including Pinealon protected neurons derived from fibroblasts against age-related changes, supporting the compound's role in combating neural aging at the cellular level.

SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome

Machiraju P, et al. · Scientific Reports · 2024

Demonstrated that SS-31 improves cardiac mitochondrial structure and restores the process of clearing damaged mitochondria in a mouse model of Barth syndrome, providing further evidence for its mechanism of structural repair.

Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction

Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. · Diabetes, Obesity and Metabolism · 2024

Most recent study showing dose-dependent weight and fat mass reduction, improved glucose tolerance and insulin sensitivity, suppressed hyperinsulinemia, and improved liver pathology markers, along with detailed pharmacokinetic characterization.

Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy

Hinder LM, et al. · International Journal of Molecular Sciences · 2024

Showed AICAR prevented and reversed diabetic peripheral neuropathy in Type 1 and Type 2 diabetes mouse models by regulating mitochondrial function through AMPK phosphorylation, with improvements in insulin sensitivity and metabolic parameters.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · New England Journal of Medicine · 2023

Cardiovascular outcomes trial with over 17,000 participants demonstrating that semaglutide reduced major adverse cardiovascular events by 20% compared to placebo in people with obesity and established heart disease.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

Jastreboff AM, Kaplan LM, Frias JP, et al. · New England Journal of Medicine · 2023

Landmark Phase 2 trial with 338 adults showing dose-dependent weight loss up to 24.2% at the 12 mg dose over 48 weeks, with 100% of participants at higher doses achieving at least 5% weight loss and 63% losing 20% or more.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

Rosenstock J, Frias JP, Jastreboff AM, et al. · The Lancet · 2023

Phase 2 trial in type 2 diabetes demonstrating approximately 17% weight loss at 36 weeks alongside HbA1c reductions of up to 2.0%, with improvements in blood pressure, triglycerides, and cholesterol markers.

Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging

Wan W, Zhang L, Lin Y, et al. · Journal of Translational Medicine · 2023

Comprehensive review of MOTS-c's effects on stress response, metabolism, and aging, covering its AMPK activation mechanism, nuclear translocation capabilities, and anti-inflammatory properties.

Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin

Rejdak K, et al. · Medicinal Research Reviews · 2023

Comprehensive review covering Cerebrolysin's mechanisms of neurotrophic factor modulation across dementia, stroke, and traumatic brain injury, including evidence that it may not benefit acute stroke mortality but supports rehabilitation outcomes.

Thymosin alpha-1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application

Tao N, et al. · Molecules · 2023

Detailed review of Thymosin Alpha-1's mechanisms in viral infectious diseases, covering its direct antiviral effects and immune enhancement pathways, including data from COVID-19 studies.

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine · 2022

The SURMOUNT-1 trial with 2,539 adults showed dose-dependent weight loss of 15% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg weekly over 72 weeks, with 36% of participants on the highest dose losing 25% or more of body weight.

Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice

Dimet-Wiley A, Wu Q, Wiley JT, et al. · Scientific Reports · 2022

Demonstrated that combining 5-Amino-1MQ with a diet switch normalized body weight and fat mass to levels indistinguishable from never-obese mice, an outcome diet switch alone could not achieve, while also beneficially altering the gut microbiome.

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine · 2021

The landmark STEP-1 trial with 1,961 adults showed that semaglutide 2.4 mg weekly produced 14.9% average weight loss over 68 weeks, with 86% of participants losing at least 5% of body weight and half losing 15% or more.

Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP-3)

Davies M, Faerch L, Jeppesen OK, et al. · The Lancet · 2021

Combined semaglutide with intensive behavioral therapy and demonstrated 16% average body weight loss, showing that lifestyle changes amplify the medication's effects beyond what either approach achieves alone.

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frias JP, Davies MJ, Rosenstock J, et al. · New England Journal of Medicine · 2021

The SURPASS-2 trial directly compared tirzepatide to semaglutide in people with type 2 diabetes and showed tirzepatide produced greater reductions in both HbA1c and body weight at all dose levels.

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide (SURPASS trials)

Rosenstock J, Wysham C, Frias JP, et al. · The Lancet Diabetes & Endocrinology · 2021

Comprehensive analysis of the SURPASS trial program confirming tirzepatide's superior efficacy for blood sugar control and weight loss across multiple patient populations with type 2 diabetes.

Once-weekly cagrilintide for weight management in people with overweight and obesity

Lau DCW, Erichsen L, Francisco-Ziller N, et al. · The Lancet · 2021

Phase 2 trial with 706 participants demonstrating dose-dependent weight loss up to 10.8% at the 4.5 mg dose over 26 weeks, outperforming liraglutide 3.0 mg head to head.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide

Enebo LB, Berthelsen KK, Kankam M, et al. · The Lancet · 2021

Phase 1b combination trial showing that cagrilintide 2.4 mg plus semaglutide 2.4 mg produced 17.1% weight loss over 20 weeks, significantly more than semaglutide alone at approximately 10%.

Development of cagrilintide, a long-acting amylin analogue

Kruse T, Hansen JL, Vestermark GL, et al. · Journal of Medicinal Chemistry · 2021

Detailed the molecular engineering behind cagrilintide, explaining how modifications to natural amylin created a compound with a 7 to 8 day half-life suitable for once-weekly dosing.

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Reynolds JC, Lai RW, Woodhead JST, et al. · Nature Communications · 2021

Demonstrated that MOTS-c improves physical performance in mice of all ages including elderly mice, confirmed that exercise induces MOTS-c expression in human skeletal muscle, and established it as an exercise-induced mitochondrial regulator.

EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease

Khavinson V, et al. · International Journal of Molecular Sciences · 2021

Demonstrated that Pinealon prevented dendritic spine elimination in Alzheimer's models, with treated neurons showing a 71% increase in functional mushroom-shaped spines critical for learning and memory, and identified specific DNA binding mechanisms.

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers

Wang X, Liu L, Qi L, et al. · Journal of Cellular and Molecular Medicine · 2021

Phase I study confirming single and multiple dose administration of thymosin beta-4 was safe and well tolerated in healthy adults, providing additional human pharmacokinetic data.

Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients

Kuznik BI, et al. · Advances in Gerontology · 2021

Study of 36 severe COVID-19 patients showing Thymalin accelerated clinical improvement, produced faster recovery from lymphopenia, restored multiple immune cell populations, and normalized inflammatory markers faster than standard therapy alone.

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome

Thompson WR, et al. · Genetics in Medicine · 2021

The pivotal TAZPOWER trial showing that while the 12-week crossover phase did not meet primary endpoints, the 36-week open-label extension demonstrated significant improvements in 6-Minute Walk Test distance (95.9 meters), symptom scores, and muscle strength in Barth syndrome patients.

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

Le HQ, Lie KK, Giroud-Gerbetant J, et al. · Frontiers in Bioengineering and Biotechnology · 2021

Confirmed FOXO4-DRI's selectivity in human cartilage cells, showing significant reduction in senescent chondrocytes while non-senescent cells were unaffected. All senescence markers decreased, suggesting applications for cartilage regeneration and joint health.

The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent

Ridyard KE, Overhage J · Antibiotics (Basel) · 2021

Up-to-date review examining LL-37's potential as both an antimicrobial and anti-biofilm agent, covering recent advances in understanding its mechanisms and efforts to develop it for clinical use.

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Yoshino M, Yoshino J, Kayser BD, et al. · Science · 2021

A clinical trial showing that 10 weeks of NMN supplementation at 250 mg daily improved skeletal muscle insulin sensitivity in overweight or obese women with prediabetes, providing some of the first direct metabolic benefit evidence in humans.

NAD+ metabolism and its roles in cellular processes during ageing

Covarrubias AJ, Perrone R, Grozio A, Verdin E · Nature Reviews Molecular Cell Biology · 2021

A detailed review of how NAD+ metabolism changes during aging, covering the roles of NAD+ in cellular processes, the enzymes that consume and produce it, and the therapeutic implications of restoring NAD+ levels.

AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review

Visnjic D, Lalic H, Dembitz V, Tomic B, Smoljo T · Cells · 2021

Systematic review confirming AICAR as one of the most commonly used AMPK activators while documenting important AMPK-independent effects on purine and pyrimidine synthesis, emphasizing the need for caution in interpreting AICAR research.

Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial

Muresanu DF, et al. · Neurological Sciences · 2020

Studied Cerebrolysin in moderate to severe TBI patients, finding improvements in neurorecovery markers for cognitive and physical function after brain injury.

Thymosin alpha 1: A comprehensive review of the literature

Dominari A, et al. · World Journal of Virology · 2020

Extensive literature review covering Thymosin Alpha-1's antiviral effects, immune modulation mechanisms, clinical applications in chronic infections, and its role as a well-tolerated immunomodulator.

Mitochondrial protein interaction landscape of SS-31

Chavez JD, et al. · Proceedings of the National Academy of Sciences · 2020

A study mapping the network of mitochondrial proteins that SS-31 interacts with, providing detailed insight into how the peptide stabilizes cardiolipin interactions and improves electron transport chain function.

FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

Zhang C, Xie Y, Chen H, et al. · Aging (Albany NY) · 2020

Demonstrated that FOXO4-DRI treatment in naturally aged mice increased serum testosterone and improved testicular function by selectively clearing senescent Leydig cells, with decreased senescence markers and increased testosterone synthesis enzymes.

Efficacy of afamelanotide for the long-term treatment of erythropoietic protoporphyria

Haylett AK, Sherwood S, Baker CS, et al. · JAMA Dermatology · 2020

Three-year observational study confirmed no serious adverse events with sustained MT-1 use, with phototoxic burn tolerance increasing 1.8 to 180 fold and patients maintaining quality-of-life improvements over the full study period.

The Science Behind NMN: A Stable, Reliable NAD+ Activator and Anti-Aging Molecule

Shade C · Integrative Medicine (Encinitas) · 2020

An overview of NMN as a stable NAD+ precursor, covering its mechanisms as an anti-aging molecule and its advantages as a supplementation strategy.

Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial

Stanley TL, Fourman LT, Feldpausch MN, et al. · Annals of Internal Medicine · 2019

Randomized, double-blind multicenter trial showed tesamorelin reduced hepatic fat fraction by 37 percent, prevented liver fibrosis progression compared to placebo, and maintained benefits over 12 months of treatment.

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing

Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research · 2019

Comprehensive review finding BPC-157 shows promise for healing tissues with poor blood supply like tendons and ligaments, with few reported adverse reactions, though nearly all research was conducted in rodent models.

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology · 2019

The pivotal RECONNECT trials that led to FDA approval, involving 1,247 premenopausal women with HSDD over 24 weeks. Demonstrated significant improvements in desire and reductions in sexual distress with 1.75 mg subcutaneous PT-141.

SCENESSE (afamelanotide) Prescribing Information

Clinuvel Pharmaceuticals · FDA Prescribing Information · 2019

Official prescribing information for the FDA-approved 16 mg subcutaneous implant formulation of afamelanotide for the treatment of erythropoietic protoporphyria in adults.

Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases

Braidy N, Berg J, Clement J, et al. · Antioxidants & Redox Signaling · 2019

A review examining NAD+ and its precursors as therapeutic targets for age-related degenerative diseases, covering the mechanisms of NAD+ decline and the evidence for supplementation strategies.

Implications of altered NAD metabolism in metabolic disorders

Okabe K, Yaku K, Tobe K, Nakagawa T · Journal of Biomedical Science · 2019

A review of how altered NAD+ metabolism contributes to metabolic disorders including diabetes and obesity, and how restoring NAD+ levels may help address these conditions.

Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures

Elhassan YS, Kluckova K, Fletcher RS, et al. · Cell Reports · 2019

A human study showing that nicotinamide riboside supplementation augments the NAD+ metabolome in aged skeletal muscle and induces gene expression changes associated with reduced inflammation and improved mitochondrial function.

Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle

Neelakantan H, Brightwell CR, Graber TG, et al. · Biochemical Pharmacology · 2019

Showed that 5-Amino-1MQ activated dormant muscle stem cells in aged mice and improved muscle regenerative capacity, with grip strength improving when treatment was combined with exercise.

Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury

Sun KT, Cheung KK, Au SWN, Yeung SS, Yeung EW · Frontiers in Physiology · 2018

Showed that MGF modulated inflammatory cytokine expression, improved recruitment of macrophages and neutrophils to injury sites, and enhanced resolution of muscle inflammation, supporting its role in the early phase of muscle repair.

The efficacy of semax in the treatment of patients at different stages of ischemic stroke

Gusev EI, Martynov MYu, Kostenko EV, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2018

Clinical study of 110 stroke patients found Semax (6,000 mcg/day for 10 days) increased BDNF plasma levels and correlated with better Barthel scores for functional independence and improved motor performance.

Semax as a universal drug for therapy and research

Koroleva SV, Myasoedov NF. · Biology Bulletin · 2018

Comprehensive review covering Semax's clinical applications, mechanisms of action, and decades of use as a prescribed medication in Russia for stroke, cognitive decline, and optic nerve disorders.

Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing

Sikiric P, et al. · Current Pharmaceutical Design · 2018

Reviewed BPC-157's role as a cytoprotective mediator with unique gastric stability, detailing its mechanisms of vascular recruitment and gastrointestinal tract healing across multiple animal models.

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

Pickart L, Margolina A · International Journal of Molecular Sciences · 2018

Comprehensive review showing GHK-Cu affects expression of over 4,000 human genes, shifting patterns toward healthier states, with effects on antioxidant defense, anti-inflammatory response, and DNA repair observed at very low concentrations.

Senolytics improve physical function and increase lifespan in old age

Xu M, Pirtskhalava T, Farr JN, et al. · Nature Medicine · 2018

A broader study on senolytic approaches showing that clearance of senescent cells improves physical function and extends lifespan in aged mice, providing context for the senolytic approach that FOXO4-DRI represents.

Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function

Sinha R, Sinha I, Calcagnotto A, et al. · European Journal of Clinical Nutrition · 2018

Study showing that liposomal glutathione supplementation increased body glutathione stores and improved markers of immune function including natural killer cell cytotoxicity and lymphocyte proliferation.

NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR

Yoshino J, Baur JA, Imai SI · Cell Metabolism · 2018

A comprehensive review covering the biology of NAD+ intermediates NMN and NR, their therapeutic potential for age-related diseases, and the mechanisms by which they restore NAD+ levels in tissues.

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Martens CR, Denman BA, Mazzo MR, et al. · Nature Communications · 2018

A human trial demonstrating that chronic supplementation with the NAD+ precursor nicotinamide riboside is safe, well-tolerated, and effectively raises NAD+ levels in healthy middle-aged and older adults.

Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects

Berlanga-Acosta J, et al. · SAGE Open Medicine · 2017

Comprehensive historical review of GHRP cytoprotective effects documenting the evidence for cardioprotective and tissue-protective properties of growth hormone releasing peptides including GHRP-6.

GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

Filatova E, Kasian A, Kolomin T, et al. · Frontiers in Pharmacology · 2017

Found that Selank altered expression of 45 genes involved in neurotransmission within one hour, with changes positively correlated with those produced by GABA itself, supporting the GABAergic mechanism of action.

Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

Kasian A, Kolomin T, Andreeva L, et al. · Behavioural Neurology · 2017

Radioligand binding studies showed Selank acts as a positive allosteric modulator of GABA receptors, competing with diazepam for binding sites but producing distinct effects through a related but different site on the receptor complex.

Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro

Hsieh MJ, Liu HT, Wang CN, et al. · Drug Design, Development and Therapy · 2017

Demonstrated that BPC-157 accelerated alkali burn wound healing through enhanced granulation tissue formation, re-epithelialization, and collagen deposition mediated by ERK1/2 signaling.

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

Xiao B, Xu Z, Viennois E, et al. · Molecular Therapy · 2017

Advanced oral delivery study showing hyaluronic acid nanoparticles loaded with KPV provided targeted delivery to colitis tissue, combining accelerated mucosal healing with reduced inflammation and enhanced therapeutic efficacy.

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

Culver DA, Dahan A, Baber D, et al. · Investigative Ophthalmology and Visual Science · 2017

Randomized, double-blind, placebo-controlled Phase 2b trial in 64 patients showing 4 mg daily ARA-290 produced a 23% increase in corneal nerve fiber area versus placebo with significant symptom improvements and no serious adverse events.

The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age

Sweetwyne MT, et al. · Kidney International · 2017

Showed that 8 weeks of SS-31 treatment in aged mice improved mitochondrial morphology, reduced senescence markers, improved kidney cell density, and reduced kidney scarring, demonstrating reversal of age-related changes at the cellular level.

Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging

Baar MP, Brandt RMC, Putavet DA, et al. · Cell · 2017

The landmark study that introduced FOXO4-DRI, demonstrating 11.73-fold selectivity for senescent cells, restoration of fitness in fast-aging mice, improved kidney and liver function, and the ability to counteract chemotherapy-induced senescence. This paper established the FOXO4-p53 interaction as a therapeutic target.

Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS

Shoemaker R, Katz D, McMahon S, Ryan J · Internal Medicine Review · 2017

MRI study documenting restoration of gray matter volume in multiple brain regions of CIRS patients treated with intranasal VIP. Patients served as their own controls with before-and-after imaging, and structural brain improvements correlated with clinical symptom resolution.

Glutathione and its antiaging and antimelanogenic effects

Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P · Clinical, Cosmetic and Investigational Dermatology · 2017

Randomized controlled trial demonstrating that oral glutathione at 500 mg daily reduced melanin index and improved skin elasticity, wrinkles, and smoothness over 12 weeks, confirming both anti-aging and skin-lightening effects.

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice

Neelakantan H, Vance V, Wetzel MD, et al. · Biochemical Pharmacology · 2017

Foundational study validating 5-Amino-1MQ as an NNMT inhibitor, showing 35% reduction in white fat mass, 30% decrease in fat cell size, increased NAD+ and SAM levels, and no change in food intake or adverse effects in diet-induced obese mice.

Targeted proapoptotic peptides depleting adipose stromal cells inhibit tumor growth

Daquinag AC, Tseng C, Zhang Y, et al. · Molecular Therapy · 2016

Explored adipotide's potential in cancer treatment, demonstrating that depleting adipose stromal cells through vascular targeting could inhibit tumor growth, highlighting the dual research applications of this compound.

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil

Aleixandre M, et al. · International Journal of Neuropsychopharmacology · 2016

Demonstrated that Cerebrolysin alone increased serum BDNF by 300% over 16 weeks, and when combined with donepezil, BDNF increased by 600%, establishing a synergistic neurotrophic effect in Alzheimer's patients.

Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke

Chang WH, et al. · BMC Neurology · 2016

Randomized controlled trial showing Cerebrolysin plus standardized rehabilitation produced better motor recovery and greater corticospinal tract changes compared to rehabilitation alone in severe motor impairment post-stroke.

Immune Modulation with Thymosin Alpha 1 Treatment

Tuthill C, Rios I, McBeath R · Vitamins and Hormones · 2016

Comprehensive review of Thymosin Alpha-1's immune modulation effects, covering its mechanisms of action, clinical trial results in hepatitis and cancer, and its favorable safety profile across thousands of patients.

RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal polypeptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing

Ryan J, Shoemaker R · Medical Research Archives · 2016

RNA sequencing study documenting widespread changes in gene expression after VIP treatment in CIRS patients, showing a molecular shift away from inflammatory profiles and improvement in metabolic pathways, confirming the biological basis for clinical improvements.

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance

Lee C, Zeng J, Drew BG, et al. · Cell Metabolism · 2015

Landmark discovery paper identifying MOTS-c as a mitochondrial-encoded peptide that regulates insulin sensitivity, prevents diet-induced obesity, and reverses age-dependent insulin resistance in mice.

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

Gauthier S, et al. · Dementia and Geriatric Cognitive Disorders · 2015

Meta-analysis confirming Cerebrolysin improved cognitive function in mild to moderate Alzheimer's disease across multiple randomized controlled trials, with benefits maintained months after treatment ended.

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase 2 clinical trial

Sosne G, Ousler GW · Clinical Ophthalmology · 2015

Randomized, placebo-controlled Phase 2 trial showing thymosin beta-4 significantly improved signs and symptoms of severe dry eye, with effects persisting after treatment ended and no serious adverse events.

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

Pickart L, Vasquez-Soltero JM, Margolina A · BioMed Research International · 2015

Reviewed GHK-Cu's activation of TGF-beta and integrin pathways, reduction of TNF-alpha induced IL-6 secretion, restoration of irradiated fibroblast viability, and wound healing effects across multiple studies.

Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction

Fu SC, Cheuk YC, Chiu WY, et al. · Journal of Orthopaedic Research · 2015

Demonstrated that GHK-Cu transiently improved healing outcomes in a rat model of ACL reconstruction, suggesting potential applications in orthopedic recovery.

Randomized controlled trial of oral glutathione supplementation on body stores of glutathione

Richie JP, Nichenametla S, Neiber W, et al. · European Journal of Nutrition · 2015

Randomized controlled trial demonstrating that oral and liposomal glutathione supplementation significantly elevated body stores of glutathione compared to placebo, with parenteral routes achieving substantially higher blood levels than oral forms.

Intranasal oxytocin administration is associated with enhanced endogenous pain inhibition and reduced negative mood states

Goodin BR, Anderson AJB, Freeman EL, et al. · Clinical Journal of Pain · 2015

Showed that 40 IU intranasal oxytocin enhanced the body's natural pain modulation systems, reduced negative mood states, and decreased anxiety compared to placebo.

Afamelanotide for erythropoietic protoporphyria

Langendonk JG, Balwani M, Anderson KE, et al. · New England Journal of Medicine · 2015

Phase 3 trials across 244 adults with EPP demonstrated that a 16 mg MT-1 implant significantly increased pain-free sun exposure time and restored quality of life to levels comparable with age-matched healthy populations, with a favorable safety profile.

AMP-activated protein kinase controls exercise training- and AICAR-induced increases in SIRT3 and MnSOD

Brandauer J, et al. · Frontiers in Physiology · 2015

Demonstrated that AMPK activation by AICAR is required for increases in SIRT3 and MnSOD protein abundance and mitochondrial respiratory complex proteins, establishing a key pathway for exercise training adaptations.

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

Stanley TL, Feldpausch MN, Oh J, et al. · JAMA · 2014

Detailed body composition analysis showed visceral fat decreased by 15 to 17 percent, liver fat decreased by up to 18 percent, lean body mass was preserved, and trunk fat showed significant reductions with tesamorelin therapy.

Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells

Fornaro M, Hinken AC, Needle S, et al. · American Journal of Physiology: Endocrinology and Metabolism · 2014

Found that MGF peptide at concentrations up to 500 ng/mL failed to increase proliferation of C2C12 cells, primary human skeletal muscle myoblasts, or primary mouse skeletal muscle stem cells, while full-length IGF-1 did produce proliferative responses in all cell types.

A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders

Seredenin SB, Kozlovskaia MM, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2014

Compared Selank to phenazepam in 60 anxiety disorder patients; Selank produced pronounced anxiolytic and mild nootropic effects, with anti-anxiety benefits lasting a week after the last dose and improved quality of life without cognitive side effects.

The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis

Medvedeva EV, Dmitrieva VG, Povarova OV, et al. · BMC Genomics · 2014

Genome-wide analysis showing Semax affected 96 genes at 3 hours post-administration in stroke models, with over half related to immune response and vascular function, explaining broad neuroprotective mechanisms.

Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon

Mendzheritskii AM, et al. · Advances in Gerontology · 2014

Showed Pinealon suppressed caspase-3 activity (the enzyme that executes cell death) in brains of old rats exposed to acute oxygen deprivation, demonstrating direct neuroprotective effects under hypoxic stress conditions.

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

Chang CH, Tsai WC, Hsu YH, Pang JH · Molecules · 2014

Showed that BPC-157 increases growth hormone receptor expression in tendon fibroblasts, providing a molecular mechanism for its tendon healing effects through downstream JAK2 signaling.

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

Brines M, Dunne AN, van Velzen M, et al. · Molecular Medicine · 2014

Demonstrated ARA-290 improved HbA1c, lipid profiles, insulin sensitivity, and neuropathy symptoms in Type 2 diabetic patients with no effect on hematocrit, confirming the absence of EPO-like erythropoietic activity.

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

Szeto HH · British Journal of Pharmacology · 2014

A detailed paper by the developer of SS-31 describing its mechanism as the first compound specifically designed to protect cardiolipin and restore mitochondrial energy production, covering its unique pharmacology and therapeutic potential.

An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA

Demaria M, Ohtani N, Youssef SA, et al. · Developmental Cell · 2014

An important study showing that senescent cells play a beneficial role in wound healing by secreting growth factors, providing context for why senolytic treatments should be used judiciously rather than continuously.

Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial

Gronberg A, Mahlapuu M, Stahle M, Whately-Smith C, Heilborn JD · Wound Repair and Regeneration · 2014

Randomized controlled trial of 34 patients showing that topical LL-37 at 0.5 mg/mL significantly improved healing of chronic venous leg ulcers compared to vehicle, with no serious adverse events attributed to the peptide.

Glutathione!

Pizzorno J · Integrative Medicine: A Clinician's Journal · 2014

Clinical review emphasizing glutathione's critical role in detoxification, immune function, and protection against chronic disease, with practical guidance on assessment and supplementation strategies for clinicians.

Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples

Behnia B, Heinrichs M, Bergmann W, et al. · Hormones and Behavior · 2014

Study of 29 couples given 24 IU intranasal oxytocin showing increased orgasm intensity, greater contentment after intercourse, women feeling more relaxed, and improved ability to share sexual desires.

Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity

Kraus D, Yang Q, Kong D, et al. · Nature · 2014

Established the scientific foundation by demonstrating that genetically knocking out NNMT protects against diet-induced obesity, validating the enzyme as a therapeutic target for metabolic disease.

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

Stier H, Vos E, Kenley D. · Journal of Endocrinology and Metabolism · 2013

Comprehensive safety analysis of AOD-9604 across six human clinical trials with over 900 participants, including extensive toxicology testing showing no genotoxic, mutagenic, or significant adverse effects.

Cerebrolysin for vascular dementia

Chen N, et al. · Cochrane Database of Systematic Reviews · 2013

Cochrane review of six randomized trials finding Cerebrolysin improved clinical symptoms and global function in vascular dementia compared to placebo, though authors noted more high-quality research is needed.

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

Dahan A, Dunne A, Swartjes M, et al. · Molecular Medicine · 2013

Confirmed ARA-290's selective innate repair receptor activation and anti-inflammatory effects, with demonstrated improvements in neuropathic symptoms and measurable increases in corneal nerve fiber density in sarcoidosis patients.

The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin

Birk AV, et al. · Journal of the American Society of Nephrology · 2013

Demonstrated that SS-31 restores energy production in damaged mitochondria specifically through its interaction with cardiolipin, providing mechanistic evidence for how the peptide achieves its protective effects in kidney tissue.

Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings

Shoemaker RC, House D, Ryan J · Health · 2013

Published study of 20 CIRS patients receiving 50 mcg VIP nasal spray four times daily, demonstrating significant reduction in symptoms and inflammatory markers, improved pulmonary function and exercise tolerance, with no significant adverse events.

The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo

Grimes PE, Hamzavi I, Lebwohl M, et al. · JAMA Dermatology · 2013

Multicenter trial showed that combining MT-1 implants with narrowband UVB phototherapy produced faster and superior repigmentation in vitiligo patients compared to phototherapy alone, with particularly strong results on the face and upper extremities.

Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats

Voicekhovskaya MA, et al. · Bulletin of Experimental Biology and Medicine · 2012

Demonstrated Pinealon's effects on cell proliferation and regeneration in skin cell cultures from both young and old rats, supporting broader anti-aging properties beyond neuroprotection.

Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials

Thome J, Doppler E. · Drugs of Today · 2012

Systematic review of safety data from clinical trials confirming Cerebrolysin is generally well tolerated, with most adverse events being mild and temporary across both dementia and stroke populations.

Thymosin beta4: a multi-functional regenerative peptide

Goldstein AL, Hannappel E, Sosne G, Kleinman HK · Expert Opinion on Biological Therapy · 2012

Comprehensive review of thymosin beta-4 as a multi-functional regenerative peptide covering its roles in wound healing, cardiac repair, neuroprotection, and immune function.

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy

Heij L, et al. · Molecular Medicine · 2012

Open-label pilot study in 8 sarcoidosis patients showing ARA-290 produced significant improvement in pain scores, increased corneal nerve fiber density, and improved quality of life measures over 28 days of treatment.

The receptor that tames the innate immune response

Brines M, Cerami A · Molecular Medicine · 2012

Characterized the innate repair receptor as distinct from the classical erythropoietin receptor, establishing the molecular basis for ARA-290's tissue-protective and anti-inflammatory effects without erythropoietic activity.

Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

Nelson ME, Bryant SM, Aks SE · Clinical Toxicology · 2012

Case report documenting serious adverse effects from MT-2 misuse, highlighting the importance of proper dosing and the risks of using unregulated compounds without medical supervision.

Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle

Chan YM, Butler JP, Sidhoum VF, Pinnell NE, Seminara SB · Journal of Clinical Endocrinology & Metabolism · 2012

Demonstrated sex differences in kisspeptin response, showing women's reactions depend on menstrual cycle phase. Women in the preovulatory phase responded while those in the follicular phase did not.

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

Barnhart KF, Christianson DR, Hanley PW, et al. · Science Translational Medicine · 2011

Primate study showing 11% average weight loss over 4 weeks with some animals losing up to 38.7% of body weight, alongside improved insulin resistance. Identified mild, reversible renal tubular injury as the primary safety concern.

Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages

Kandalla PK, Goldspink G, Butler-Browne G, Mouly V · Mechanisms of Ageing and Development · 2011

Demonstrated that MGF E-peptide significantly increased proliferative lifespan of satellite cells from neonatal and young adult muscle, delayed senescence, and increased fusion potential, suggesting potential to combat age-related sarcopenia.

Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages

Kandalla PK, Goldspink G, Butler-Browne G, Mouly V · Mechanisms of Ageing and Development · 2011

Foundational study showing MGF E-peptide significantly increased satellite cell proliferative lifespan, delayed senescence, and increased fusion potential, with the researchers concluding it could combat age-related sarcopenia without oncogenic side effects of full-length IGF-1.

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH · Journal of Applied Physiology · 2011

Demonstrated that BPC-157 significantly accelerated tendon cell outgrowth, increased cell survival under oxidative stress, and enhanced cell migration in a dose-dependent manner through the FAK-paxillin pathway.

Natural and synthetic cathelicidin peptides with antimicrobial and antibiofilm activity against Staphylococcus aureus

Dean SN, Bishop BM, van Hoek ML · BMC Microbiology · 2011

Demonstrated that both natural LL-37 and synthetic cathelicidin peptide variants exhibit potent antimicrobial and antibiofilm activity against Staphylococcus aureus, including drug-resistant strains.

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men

George JT, Veldhuis JD, Roseweir AK, et al. · Journal of Clinical Endocrinology & Metabolism · 2011

Dose-response study showing kisspeptin-10 produced a 3-fold increase in LH within 30 minutes in healthy men. A 22.5-hour infusion increased testosterone from 16.6 to 24.0 nmol/L and enhanced LH pulse frequency and size.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

Falutz J, Potvin D, Mamputu JC, et al. · Journal of Acquired Immune Deficiency Syndromes · 2010

Pivotal Phase III trial in 404 HIV-infected patients showing tesamorelin reduced visceral adipose tissue by approximately 18 percent compared to placebo, improved body image distress scores, and was well tolerated without significant perturbation of glucose metabolism.

Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin Beta-4 in the Dystrophin Deficient Mouse

Spurney CF, Cha HJ, Sali A, et al. · PLoS ONE · 2010

Showed improved skeletal and cardiac muscle function and demonstrated long-term tolerability of thymosin beta-4 in a mouse model of Duchenne muscular dystrophy.

A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

Ruff D, Crockford D, Girardi G, Zhang Y · Annals of the New York Academy of Sciences · 2010

Established that IV thymosin beta-4 was safe and well tolerated in healthy volunteers with no significant adverse effects, providing preliminary human pharmacokinetic data.

Antiviral activity of immunomodulator Selank in experimental influenza infection

Ershov FI, et al. · Voprosy Virusologii · 2009

Demonstrated Selank's antiviral properties in experimental influenza models, supporting the immunomodulatory benefits retained from its parent molecule tuftsin.

Role of topical peptides in preventing or treating aged skin

Gorouhi F, Maibach HI · International Journal of Cosmetic Science · 2009

Reviewed the role of peptides including GHK-Cu in anti-aging skin care, examining evidence for efficacy in preventing and treating photoaged skin.

Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections

Nijnik A, Hancock RE · Emerging Health Threats Journal · 2009

Review of host defense peptides including LL-37, covering their dual antimicrobial and immunomodulatory activities and their potential as a new class of therapeutics against antibiotic-resistant infections.

Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict

Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M · Biological Psychiatry · 2009

Demonstrated that intranasal oxytocin promotes more positive communication behavior between romantic partners during conflict and reduces the stress hormone cortisol.

Mechano-growth factor ameliorates loss of cardiac function in acute myocardial infarction

Carpenter V, Matthews K, Devlin G, et al. · Heart, Lung and Circulation · 2008

Demonstrated that MGF E-domain peptide improved cardiac function in sheep after induced heart attacks, with 35 percent less compromised cardiac muscle compared to controls, working through inhibition of apoptosis in the infarct border zone.

Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia

Zozulia AA, Neznamov GG, Siuniakov TS, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008

Compared Selank to medazepam in 62 patients with GAD and neurasthenia; both showed similar anxiety reductions on Hamilton and Zung scales, but Selank also produced energy-boosting and psychostimulant effects absent in the benzodiazepine group.

PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. · Gastroenterology · 2008

Landmark study demonstrating that nanomolar concentrations of KPV inhibit NF-kappa-B and MAP kinase pathways through PepT1 transporter uptake, reducing colitis severity in two mouse models and establishing the mechanistic basis for oral KPV in gut inflammation.

Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects In Vitro and In Vivo

Brzoska T, Luger TA, Maaser C, et al. · Endocrine Reviews · 2008

Comprehensive review confirming KPV exerts similar or more pronounced anti-inflammatory activity than full-length alpha-MSH, with effectiveness in animal models of contact dermatitis, arthritis, colitis, and asthma, and a low toxicity profile.

Human host defense peptide LL-37 prevents bacterial biofilm formation

Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE · Infection and Immunity · 2008

Showed that LL-37 prevents bacterial biofilm formation by Pseudomonas aeruginosa at concentrations below those needed to kill bacteria, revealing an important anti-biofilm mechanism independent of direct killing.

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects

Brzoska T, Luger TA, Maaser C, et al. · Endocrine Reviews · 2008

Comprehensive review of melanocortin peptides including MT-2, covering their biochemistry, anti-inflammatory properties, and protective effects, as well as future therapeutic perspectives.

AMPK and PPARdelta agonists are exercise mimetics

Narkar VA, Downes M, Yu RT, et al. · Cell · 2008

Landmark study showing sedentary mice treated with AICAR for 4 weeks increased running endurance by 44% without training, induced 32 genes linked to oxidative metabolism, and decreased fat mass through the AMPK-PPARdelta pathway.

Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy

Grunfeld C, Thompson M, Brown SJ, et al. · New England Journal of Medicine / Journal of Acquired Immune Deficiency Syndromes · 2007

Study of 412 HIV patients receiving 2 mg daily tesamorelin or placebo for 26 weeks showed 15 to 20 percent reduction in visceral fat via CT scan, preserved lean mass, dropped triglycerides by about 50 points, and reduced cholesterol by about 30 percent.

Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs

Luger TA, Brzoska T · Annals of the Rheumatic Diseases · 2007

Reviewed alpha-MSH related peptides including KPV as a new class of anti-inflammatory and immunomodulating drugs with potential applications in rheumatic and inflammatory diseases.

Normalizing effect of pineal gland peptides on melatonin rhythm in old monkeys and elderly people

Korkushko OV, et al. · Advances in Gerontology · 2007

Showed that pineal peptides including Epithalon normalize melatonin rhythms in both aged monkeys and elderly human subjects.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL, et al. · Journal of Clinical Endocrinology & Metabolism · 2006

Two randomized, placebo-controlled, double-blind trials in healthy adults aged 21 to 61 showed CJC-1295 with DAC increased growth hormone 2 to 10 fold for over 6 days, increased IGF-1 1.5 to 3 fold for 9 to 11 days, and demonstrated cumulative effects with repeated dosing. Well tolerated with no serious adverse reactions.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Ionescu M, Frohman LA · Journal of Clinical Endocrinology & Metabolism · 2006

Demonstrated that CJC-1295 preserves the natural pulsatile pattern of growth hormone secretion even during continuous stimulation, suggesting the peptide works with the body's natural rhythm rather than overriding it.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

Alba M, et al. · American Journal of Physiology: Endocrinology and Metabolism · 2006

Studied CJC-1295 in mice lacking normal GHRH signaling and found that once-daily administration normalized growth patterns, with treated animals reaching normal body weight and length.

Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?

Walker RF · Clinical Interventions in Aging · 2006

Comprehensive review arguing that Sermorelin offers advantages over synthetic HGH for adult growth hormone replacement, including preservation of natural feedback mechanisms, pulsatile release patterns, and pituitary function support.

Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. · Brain Research · 2006

Demonstrated that a single intranasal Semax dose increased BDNF protein by 1.4-fold, BDNF mRNA by 3-fold, and TrkB phosphorylation by 1.6-fold in the hippocampus, with treated animals showing enhanced conditioned avoidance reactions.

LL-37, the only human member of the cathelicidin family of antimicrobial peptides

Durr UH, Sudheendra US, Ramamoorthy A · Biochimica et Biophysica Acta · 2006

Comprehensive review establishing LL-37 as the sole human cathelicidin antimicrobial peptide, covering its structure, mechanism of action, and broad-spectrum antimicrobial activity against bacteria, viruses, and fungi.

Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse

Alba M, et al. · American Journal of Physiology: Endocrinology and Metabolism · 2005

Showed that GHRP-2 requires an intact GHRH system to fully stimulate growth hormone release, as GHRP-2 alone could not stimulate adequate GH secretion in GHRH knockout mice, supporting the rationale for combining GHRPs with GHRH peptides.

Mechanical signals, IGF-I gene splicing, and muscle adaptation

Goldspink G · Physiology · 2005

Established that MGF is expressed as a pulse by mechanically overloaded muscle and is involved in tissue repair and adaptation, with elderly individuals showing reduced ability to upregulate MGF in response to exercise.

A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia

Dluzniewska J, Sarnowska A, Beresewicz M, et al. · FASEB Journal · 2005

Demonstrated that the MGF E-peptide has strong neuroprotective effects in brain ischemia models, suggesting applications of MGF beyond skeletal muscle repair and into neurological protection.

Mechanical signals, IGF-I gene splicing, and muscle adaptation

Goldspink G · Physiology · 2005

Established that MGF is expressed as a pulse by mechanically overloaded muscle, is involved in tissue repair and adaptation, and that elderly individuals show reduced ability to upregulate MGF in response to exercise compared to younger people.

Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents

Eremin KO, Kudrin VS, Saransaari P, et al. · Neurochemical Research · 2005

Showed Semax activates both dopaminergic and serotonergic systems, increasing serotonin metabolites by approximately 25% in the striatum and potentiating dopamine release when combined with amphetamine.

Role of vasoactive intestinal peptide in inflammation and autoimmunity

Gonzalez-Rey E, Delgado M · Current Opinion in Investigational Drugs · 2005

Review covering VIP's therapeutic potential in inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, based on preclinical and early clinical evidence.

Oxytocin increases trust in humans

Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E · Nature · 2005

Landmark study demonstrating that intranasal oxytocin increased trust in an economic game paradigm, with participants more willing to invest money with strangers. Established oxytocin's role in human social decision-making.

Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males

Dhillo WS, Chaudhri OB, Patterson M, et al. · Journal of Clinical Endocrinology & Metabolism · 2005

Early human study establishing that kisspeptin stimulates the HPG axis in men, increasing LH, FSH, and testosterone levels. Confirmed kisspeptin's role as a key regulator of reproductive hormones.

Reversal of obesity by targeted ablation of adipose tissue

Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. · Nature Medicine · 2004

Original discovery paper demonstrating that targeting the blood vessels feeding white adipose tissue with a proapoptotic peptide caused rapid and dramatic fat loss in obese mice, establishing the concept of vascular-targeted fat destruction.

Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair

Bock-Marquette I, Saxena A, White MD, et al. · Nature · 2004

Landmark study demonstrating that thymosin beta-4 activates integrin-linked kinase, promotes cardiac cell migration and survival, and stimulates formation of new heart muscle cells from precursor cells.

Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling

Romani L, et al. · Blood · 2004

Demonstrated Thymosin Alpha-1's mechanism of action through TLR-2 and TLR-9 agonist activity, showing activation of dendritic cells through Toll-like receptor signaling and induction of antifungal immune resistance.

The significance of vasoactive intestinal peptide in immunomodulation

Delgado M, Pozo D, Ganea D · Pharmacological Reviews · 2004

Comprehensive review of VIP's immunomodulatory role, detailing how it reduces pro-inflammatory cytokines, increases anti-inflammatory cytokines, promotes regulatory T cell development, and suppresses autoimmune Th17 responses.

Glutathione metabolism and its implications for health

Wu G, Fang YZ, Yang S, Lupton JR, Turner ND · Journal of Nutrition · 2004

Foundational review covering glutathione's role in antioxidant defense, detoxification, immune function, and cellular protection, establishing it as the body's most important endogenous antioxidant with implications for numerous health conditions.

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141

Diamond LE, Earle DC, Rosen RC, et al. · International Journal of Impotence Research · 2004

Early clinical evaluation showing PT-141 produced significant improvements in erectile function in men, with 33.5% showing positive results versus 8.5% on placebo.

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141

Rosen RC, Diamond LE, Earle DC, et al. · International Journal of Impotence Research · 2004

Demonstrated the safety and efficacy of subcutaneous PT-141 in men, establishing the pharmacokinetic profile and confirming erectile response enhancement.

Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers

Barnetson RS, Ooi TK, Zhuang L, et al. · Archives of Dermatology · 2004

Three Phase 1 clinical trials at Arizona Health Sciences Center demonstrated that MT-1 combined with UV exposure produced significantly enhanced tanning and 47% fewer sunburn cells compared to controls, with side effects limited to mild nausea and flushing.

Growth hormone-releasing hormone and growth hormone secretagogues in normal aging

Merriam GR, et al. · Endocrine · 2003

Study demonstrating that Sermorelin and growth hormone secretagogues offer advantages in normal aging by preserving somatostatin feedback regulation, maintaining pulsatile release, avoiding tolerance, and supporting pituitary function.

Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B

Li Y, et al. · Clinical and Experimental Medicine · 2003

Showed significant increases in intrahepatic NKT cells and CD8+ cytotoxic T lymphocytes, decreased disease activity scores, with elevated immune cells maintained through end of treatment.

Peptides of pineal gland and thymus prolong human life

Khavinson V, Morozov V · Neuroendocrinology Letters · 2003

Landmark 6-8 year clinical trials in 266 elderly patients showing Thymalin normalized multiple organ system measurements, reduced mortality 2.0-2.1 fold alone and 4.1 fold with 6-year annual combined Thymalin/Epithalamin treatment, and reduced acute respiratory disease 2.0-2.4 fold.

Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

Khavinson VK, Bondarev IE, Butyugov AA · Bulletin of Experimental Biology and Medicine · 2003

This foundational study demonstrated that Epithalon induces telomerase gene expression, increases telomerase enzyme activity, and elongates telomeres in human fetal fibroblast cultures. Treated cells exceeded the normal Hayflick limit, showing that Epithalon can extend the replicative potential of normal human cells.

Peptide correction of age-related pineal disturbances in monkeys

Goncharova ND, Vengerin AA, Shmaliy AV, Khavinson VK · Advances in Gerontology · 2003

This monkey study directly compared Epithalamin and synthetic Epithalon and found that Epithalon at 10 micrograms per day produced the same melatonin restoration as Epithalamin at 5 mg per day, revealing a 500-fold potency difference between the crude extract and the synthetic peptide.

Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice

Anisimov VN, Khavinson VK, Popovich IG, et al. · Biogerontology · 2003

Epithalon increased mean lifespan by approximately 13 percent in female mice, reduced spontaneous tumor incidence, and decreased metastases, demonstrating both geroprotective (anti-aging) and oncostatic (anti-cancer) properties.

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Petkov V, Mosgoeller W, Ziesche R, et al. · Journal of Clinical Investigation · 2003

Study demonstrating that inhaled VIP reduces pulmonary artery pressure and improves exercise capacity in patients with primary pulmonary hypertension, establishing VIP as a potential treatment for this serious vascular condition.

PT-141: a melanocortin agonist for the treatment of sexual dysfunction

Molinoff PB, Shadiack AM, Earle D, et al. · Annals of the New York Academy of Sciences · 2003

Foundational paper establishing PT-141 as a melanocortin receptor agonist for sexual dysfunction, detailing its mechanism of action through central nervous system pathways.

The GPR54 gene as a regulator of puberty

Seminara SB, Messager S, Chatzidaki EE, et al. · New England Journal of Medicine · 2003

Landmark study demonstrating that mutations in the kisspeptin receptor GPR54 cause absent puberty in humans, establishing kisspeptin as a critical regulator of reproductive development.

Invited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation

Adams GR · Journal of Applied Physiology · 2002

Demonstrated that IGF-1 induces proliferation and differentiation of muscle satellite cells, enabling hypertrophic adaptations in response to mechanical overload, supporting the mechanism underlying IGF-1 LR3's effects on muscle growth through both hypertrophy and hyperplasia.

Peptides and Ageing

Khavinson VK · Neuroendocrinology Letters · 2002

Comprehensive review confirming Thymalin's immune stimulation, anticarcinogenic activity, and geroprotective properties demonstrated in clinical trials, establishing the foundation for peptide bioregulation as an anti-aging strategy.

Geroprotective effect of thymalin and epithalamin

Khavinson VK, et al. · Advances in Gerontology · 2002

Detailed analysis of the geroprotective effects of Thymalin and Epithalamin, documenting the synergistic benefits of combining thymic and pineal peptides for longevity and showing the strongest effects with sustained annual treatment courses.

Peptides and Ageing

Khavinson VK · Neuroendocrinology Letters · 2002

A comprehensive review of peptide bioregulation and aging by the developer of Epithalon, covering decades of research on pineal peptides and their effects on the aging process.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. · Endocrinology · 2001

Demonstrated that AOD-9604's fat-burning effects require beta-3 adrenergic receptors, confirmed the compound does not bind growth hormone receptors, and showed it can restore beta-3 receptor expression in obese mice to lean levels.

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

Andersen NB, et al. · Growth Hormone & IGF Research · 2001

Demonstrated that Ipamorelin counteracted glucocorticoid-induced decreases in bone formation, increased bone formation rate by up to four fold, and improved bone mineral content in adult rats.

Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys

Khavinson VK, et al. · Neuroendocrinology Letters · 2001

Demonstrated that Epithalon restores disrupted neuroendocrine regulation in aging monkeys, normalizing melatonin and cortisol rhythms.

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ, Gianello R. · Hormone Research · 2000

Early metabolic characterization of AOD-9604 demonstrating its lipolytic properties and confirming that it does not affect glucose metabolism or IGF-1 levels, distinguishing it from full-length growth hormone.

The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine

Azain MJ, et al. · Domestic Animal Endocrinology · 2000

Demonstrated dose-dependent GH release peaking at 15 minutes, consistent GH stimulation over 30 days of chronic daily administration, 22.35 percent increase in average daily gain, and 20.64 percent improvement in feed efficiency.

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

Prakash A, Goa KL · BioDrugs · 1999

Review of Sermorelin's use in pediatric growth hormone deficiency showing effectiveness in promoting growth with height velocity increases sustained over 36 months and growth rate improvement in 74 percent of children.

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Gobburu JV, et al. · Pharmaceutical Research · 1999

Dose-escalation study in 40 healthy male volunteers showing a half-life of approximately 2 hours, growth hormone peak at 40 minutes post-injection, dose-dependent responses across all tested doses, and good tolerability.

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Johansen PB, et al. · Growth Hormone & IGF Research · 1999

Showed dose-dependent increases in bone growth rate from 42 to 52 micrometers per day, pronounced body weight gain, and unchanged pituitary GH content demonstrating no suppression of natural production.

Identification and characterization of a new growth hormone-releasing peptide receptor in the heart

Bhogal R, et al. · Circulation Research · 1999

Identified a novel class of Hexarelin receptors in cardiovascular tissue with highest concentrations in the heart ventricles. Demonstrated dose-dependent increases in coronary perfusion pressure through L-type calcium channels and protein kinase C pathways.

Thymosin beta4 accelerates wound healing

Malinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology · 1999

Foundational wound healing study showing thymosin beta-4 increased re-epithelialization by 42% at day 4 and 61% at day 7, improved wound contraction, and stimulated skin cell migration at concentrations as low as 10 picograms.

Ipamorelin, the first selective growth hormone secretagogue

Raun K, et al. · European Journal of Endocrinology · 1998

Landmark study establishing Ipamorelin as the first selective growth hormone secretagogue, showing GH release comparable to GHRP-6 without increases in ACTH, cortisol, prolactin, FSH, LH, or TSH even at doses 200 times higher than the effective GH-releasing dose.

Growth hormone-releasing peptide (GHRP)

Bowers CY · Cellular and Molecular Life Sciences · 1998

Foundational review by the original developer of GHRP-6, documenting the discovery and characterization of growth hormone releasing peptides and their mechanism of action through the then-novel GHS receptor.

Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man

Arvat E, et al. · Peptides · 1997

Comparative study in humans showing both GHRP-2 and Hexarelin effectively release growth hormone but also cause dose-dependent increases in ACTH, cortisol, and prolactin, unlike the more selective Ipamorelin.

Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature

Pihoker C, et al. · Journal of Clinical Endocrinology and Metabolism · 1997

Study of 15 children receiving intranasal GHRP-2 showing height velocity increased from 3.7 to 6.1 cm/year at 6 months, maintained at 6.0 cm/year at 18-24 months. Well tolerated with significantly increased GH binding protein concentrations.

IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys

Tomas FM, Walton PE, Dunshea FR, Ballard FJ · Journal of Endocrinology · 1997

Demonstrated that IGF-1 DES was 2 to 3 times more potent than IGF-1 at lowering blood sugar in vivo, confirming that reduced IGFBP binding translates to greater biological activity in living systems, with extended effects on skeletal muscle anabolism.

Natural and synthetic thymic peptides as therapeutics for immune dysfunction

Morozov VG, Khavinson VK · International Journal of Immunopharmacology · 1997

Characterized Thymalin's mechanism including isolation of the key dipeptide l-Glu-l-Trp, demonstration of T-cell differentiation activation, cytokine modulation, and neutrophil function enhancement.

Growth hormone and the insulin-like growth factor system in myogenesis

Florini JR, et al. · Endocrine Reviews · 1996

Comprehensive review of the role of the IGF system in muscle cell development and growth, detailing how IGF-1 promotes satellite cell proliferation, differentiation, and fusion into mature muscle fibers.

Reduced intravenous glutathione in the treatment of early Parkinson's disease

Sechi G, Deledda MG, Bua G, et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 1996

Pilot study evaluating intravenous glutathione in early Parkinson's disease patients, showing temporary symptom improvement that supports the role of oxidative stress in neurodegeneration, though effects did not persist long-term.

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study

Dorr RT, Lines R, Levine N, et al. · Life Sciences · 1996

Phase 1 human trial demonstrating that subcutaneous MT-2 produced visible skin tanning with as few as 5 doses. Side effects included nausea, flushing, and spontaneous erections lasting 1 to 5 hours.

Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells

Adams EF, et al. · Journal of Endocrinology · 1995

Demonstrated that GHRP-6 stimulates phosphatidylinositol turnover dose-dependently in human pituitary cells, with growth hormone secretion increasing in parallel. Effects detectable after 15 minutes, maximum at 2 hours, confirmed in 8 of 8 tumors examined.

Growth hormone-releasing activity of hexarelin in humans: a dose-response study

Imbimbo BP, et al. · European Journal of Clinical Pharmacology · 1994

Double-blind, placebo-controlled, rising-dose study demonstrating that Hexarelin stimulates dose-dependent, reproducible growth hormone release in humans via subcutaneous administration and is well tolerated.

GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats

Deghenghi R, et al. · Life Sciences · 1994

Demonstrated that subcutaneous Hexarelin produced long-lasting growth hormone release in both infant and adult rats, slightly more effective than GHRP-6, and described it as a highly effective growth hormone releaser.

Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism

Fryburg DA · American Journal of Physiology · 1994

Established that IGF-1 exerts direct anabolic effects on human muscle protein metabolism, including enhanced protein synthesis and insulin-like metabolic actions on muscle tissue.

In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds

Maquart FX, Pickart L, Laurent M, et al. · Journal of Clinical Investigation · 1993

Landmark study showing GHK-Cu increased collagen synthesis 9-fold in treated wounds, accelerated wound contraction, and enhanced epithelialization while activating fibroblasts and mast cells.

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study

Schneider-Helmert D. · Neuropsychobiology · 1992

Double-blind study in 16 chronic insomnia patients showing higher sleep efficiency and shorter sleep latency with DSIP versus placebo, though effects were modest with short-term treatment.

Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin

Levine N, Sheftel SN, Eytan T, et al. · JAMA · 1991

Early study establishing that synthetic melanotropins like MT-2 could induce skin pigmentation through subcutaneous administration, laying the groundwork for further clinical development.

Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1

Ross M, Francis GL, Szabo L, et al. · Biochemical Journal · 1989

Showed that while binding proteins blocked the growth-promoting activities of IGF-1 and IGF-2, IGF-1 DES was completely unaffected by these binding proteins. The biological potencies of different IGF forms correlated inversely with their IGFBP binding.

Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH

Hiltz ME, Lipton JM · FASEB Journal · 1989

Early discovery work demonstrating the anti-inflammatory and anti-pyretic activity of the C-terminal alpha-MSH fragment, establishing KPV as the active anti-inflammatory sequence of the parent molecule.

Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder

Lesch KP, et al. · Biological Psychiatry · 1988

Found that DSIP and cortisol concentrations were highly correlated and elevated in depressed patients versus controls, supporting DSIP's modulatory role in the HPA axis and its significance in stress-related conditions.

Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding

Ballard FJ, Francis GL, Ross M, et al. · Biochemical and Biophysical Research Communications · 1987

Foundational study showing IGF-1 DES is approximately 10-fold more potent than native IGF-1 at stimulating cell hypertrophy and proliferation due to greatly reduced binding to IGF binding proteins while retaining full IGF-1 receptor affinity.

Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats

Clark RG, Jansson JO, Isaksson O, Robinson IC · Journal of Endocrinology · 1985

Compared IGF-1 and IGF-1 DES in growth hormone deficient mice, finding that just 3 mcg of IGF-1 DES daily produced growth effects equivalent to 30 mcg of IGF-1, demonstrating the ten-fold potency advantage.

Delta-sleep-inducing peptide (DSIP): a review

Graf MV, Kastin AJ. · Neuroscience and Biobehavioral Reviews · 1984

Comprehensive review covering DSIP's discovery, distribution throughout the brain and body, mechanisms of action, and clinical potential for sleep disorders, pain, and withdrawal syndromes.

Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep

Schneider-Helmert D, Schoenenberger GA. · Neuropsychobiology · 1983

Demonstrated that DSIP increased total sleep time by 59% in healthy volunteers without pharmacological sedation, with delayed benefits including shorter sleep onset and improved sleep efficiency on subsequent nights.

Characterization of a delta-electroencephalogram (delta-sleep)-inducing peptide

Schoenenberger GA, Monnier M. · Proceedings of the National Academy of Sciences USA · 1977

The original discovery and characterization of DSIP, isolated from the blood of rabbits induced into slow-wave sleep, establishing the peptide's identity and its association with delta sleep.